Psychedelics in Palliative Care

Bottom line: Psychedelic-assisted therapies may suggest relief from depression, anxiety, and existential distress in palliative care patients, but evidence remains limited and requires further study.

A patient with a life-limiting illness, after failing to find relief from emotional suffering, might sit in a quiet room, staring at the ceiling. They’ve tried medication, therapy, and support groups. But the weight of their condition remains. This is the point where psychedelic-assisted therapies (PAT) come into focus — a treatment that, according to some recent studies, may help ease depression, anxiety, and a deep sense of meaninglessness.

The State of Psychedelic-Assisted Therapies

A review of 22 studies on PAT in palliative care shows that these therapies consistently reduced depression, anxiety, and existential distress. Patients also reported better quality of life and spiritual well-being. But the way these therapies are delivered varied. Some programs included thorough preparation and follow-up, while others skipped critical steps like proper training for clinicians or a supportive environment. This inconsistency raises questions about how reliably these benefits can be replicated.

Mechanisms and Efficacy

Psilocybin, a compound in magic mushrooms, appears to work by activating serotonin 5-HT2A receptors in the brain. This can alter neural activity and promote plasticity — the brain’s ability to change. In some trials, patients saw significant improvements in depression and anxiety after just one or two sessions. A review of 11 placebo-controlled trials and four open-label studies found that psilocybin and ketamine both had large, rapid effects on mental health symptoms.

Context and Limitations

Despite these results, the evidence is still limited. Most studies are small, and their methods vary. Some lack proper blinding, and the people who participated were often not representative of the broader palliative care population. Also, these therapies are expensive and require a lot of support from trained professionals. Legal and regulatory challenges also stand in the way of wider adoption.

Frequently asked questions

• What are psychedelic-assisted therapies, and how do they work?
  Psychedelic-assisted therapies use compounds like psilocybin and ketamine in combination with therapy to treat mental health conditions, including depression and anxiety.

• Are psychedelic-assisted therapies safe, and what are the potential risks?
  Most studies report few serious side effects. Some people experience mild nausea or headaches during the session, but these usually pass.

• Can psychedelic-assisted therapies be used in conjunction with conventional treatments?
  Yes. These therapies can be used alongside other treatments like antidepressants and psychotherapy.

• What are the potential benefits of psychedelic-assisted therapies in palliative care?
  They may help reduce depression, anxiety, and existential distress, and improve quality of life and spiritual well-being.

• Are psychedelic-assisted therapies widely available, and what are the challenges to accessibility?
  Not yet. High costs, limited access due to the intensive nature of the therapy, and legal barriers are major obstacles.

Sources

• ¶Psychedelic-Assisted Interventions in Palliative Care: A Narrative Overview and Critical Evaluation
• ¶Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis
• ¶PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.